Atara Biotherapeutics, Inc. (ATRA) News
Filter ATRA News Items
ATRA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ATRA News Highlights
- ATRA's 30 day story count now stands at 2.
- Over the past 9 days, the trend for ATRA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest ATRA News From Around the Web
Below are the latest news stories about ATARA BIOTHERAPEUTICS INC that investors may wish to consider to help them evaluate ATRA as an investment opportunity.
Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre LaboratoriesTHOUSAND OAKS, Calif., December 20, 2023--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the closing of the expanded global partnership with Pierre Fabre Laboratories for tabelecleucel (tab-cel® or EBVALLOTM). Building on the earlier partnership announced in October 2021 to commercialize tab-c |
Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual MeetingTHOUSAND OAKS, Calif., December 11, 2023--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced preclinical data on ATA3431, a next-generation allogeneic CD20/CD19-dual targeted chimeric antigen receptor (CAR) EBV T-cell therapy candidate. Findings support ATA3431 advancement into clinical testing, i |
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)THOUSAND OAKS, Calif., December 01, 2023--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 27,000 restricted stock units of Atara’s common stock to three newly hired employees. These awards were approved by the Compensation Committee of Atara’s Board of Directors and granted under th |
Atara Biotherapeutics To Present Positive New Tab-cel® Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023THOUSAND OAKS, Calif., November 29, 2023--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced positive new data for tabelecleucel (tab-cel® or EBVALLO™) in patients with relapsed or refractory (r/r) or treatment-naïve Epstein-Barr virus-positive post-transplant lymphoproliferative disease involving |
Atara Biotherapeutics (ATRA) Slumps 57% in a Month: Here's WhyAtara's (ATRA) shares fell after a phase II study evaluating its multiple sclerosis therapy did not meet its primary endpoint. |
Atara Biotherapeutics to Participate at the 6th Annual Evercore ISI HealthCONx ConferenceTHOUSAND OAKS, Calif., November 22, 2023--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 10:50 a.m. EST. |
Billionaire Seth Klarman’s Biotech Stock PicksIn this article, we discuss billionaire Seth Klarman’s biotech stock picks. To skip the detailed analysis of the biotech industry, Seth Klarman’s investment philosophy, and Baupost Group’s performance and Q3 bets, go directly to Billionaire Seth Klarman’s Top 4 Biotech Stock Picks. Biotechnology is the technology segment that utilizes cellular and biomolecular processes for the […] |
Atara Biotherapeutics To Participate at the Stifel Healthcare ConferenceTHOUSAND OAKS, Calif., November 10, 2023--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a fireside chat at the Stifel Healthcare Conference in New York on Tuesday, November 14, 2023 at 8:30 a.m. PST / 11:30 a.m. E |
Astra Space (ASTR) Stock Spikes 82% on Take-Private ProposalAstra Space stock is taking off on Thursday as investors react to a take-private offer for ASTR shares from the company's founders. |
Why Is Assertio (ASRT) Stock Down 39% Today?Assertio stock is dropping on Thursday as investors in ASRT react to the company's poor earnings results for the third quarter of 2023. |